Skip to main content
Leiden University
Scholarly Publications
Home
Submit
About
Select Collection
All collections
Academic speeches
Dissertations
Faculty of Archaeology
Faculty of Governance and Global Affairs
Faculty of Humanities
Faculty of Science
Faculty of Social and Behavioural Sciences
Leiden Journals, Conference Proceedings and Books
Leiden Law School
Leiden University Press
Medicine / Leiden University Medical Centre (LUMC)
Research output UL
Search box
Your Search
Enabled Filters
(-)
= Samanta, S.
Sort Options
Date (year)
Author / Creator
Title
Refine Results
Resource Type
Article / Letter to editor
(3)
+
-
Availability
Metadata Only
(3)
+
-
Creation Date
2016
(2)
+
-
Faculty
Leiden University Medical Center (LUMC)
(3)
+
-
Collection
Medicine / Leiden University Medical Centre (LUMC)
(3)
+
-
Author
Heijde, D. van der
(3)
+
-
Samanta, S.
(3)
+
-
Vangerow, H.
(3)
+
-
Cuchacovich, R.
(2)
+
-
Gladman, D.
(2)
+
-
Lee, C.H.
(2)
+
-
Lin, C.Y.
(2)
+
-
Mease, P.
(2)
+
-
Ritchlin, C.
(2)
+
-
Shuler, C.
(2)
+
-
Show more
Language
en
(3)
+
-
Search results
(1 - 3 of 3)
show grid
show list
save search
Mease, P.J.; Heijde, D. van der; Ritchlin, C.T.; Cuchacovich, R.S.; Shuler, C.L.; Lin, C.; ... ; Gladman, D.D.
2017
A randomized, double-blind, active-and placebo-controlled phase 3 study of efficacy and safety of ixekizumab, adalimumab, and placebo therapy in patients naive to biologic disease-modifying antirheumatic drugs with active psoriatic arthritis
Article / Letter to editor
metadata only
Mease, P.; Heijde, D. van der; Ritchlin, C.; Cuchacovich, R.; Shuler, C.; Lin, C.Y.; ... ; Larsson, E.
2016
The efficacy and safety of ixekizumab, adalimumab, and placebo in patients with psoriatic arthritis naive to biological disease-modifying anti-rheumatic drugs: a double-blind phase 3 study
Article / Letter to editor
metadata only
Mease, P.; Heijde, D. van der; Ritchlin, C.; Cuchacovich, R.; Shuler, C.; Lin, C.Y.; ... ; Gladman, D.
2016
A Randomized, Double-blind, Active-and Placebo-controlled Phase 3 Study of Efficacy and Safety of Ixekizumab, Adalimumab, and Placebo Therapy in Patients Naive to Biologic Disease Modifying Antirheumatic Drugs with Active Psoriatic Arthritis
Article / Letter to editor
metadata only